Coronary Artery Disease Clinical Trial
Official title:
Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease
1. The primary purpose of this study is to determine the diagnostic accuracy of the CADscore
System, a new danish technology that records sounds from turbulence of bloodflow in the
coronary vessels.
And secondary:
1. To determine the accuracy of cardiac magnetic resonance imaging (MRI) and single-photon
emission computed tomography (SPECT), as secondary tests after detection of obstructive
anatomic coronary artery stenosis by coronary computed tomographic angiography (CCTA).
2. To examine the patient population for bio-genetic markers related to development of
arteriosclerosis.
3. To evaluate virtual fractional flow reserve (vFFR) computed from coronary angiograms.
Primary study CCTA is currently the first choice to rule out coronary artery disease (CAD)
in patients with typical or atypical chest pain. 4500 patients are annually examined with
CCTA, in the Central Jutland Region of Denmark, and approximately 80% are discharged after
ruling out CAD. CCTA is a diagnostic scan that exposes the patients to radiation, therefore
a better risk stratification prior to the test is desirable. The CADscore is a newly
developed danish technology that has been tested so far in 1000 patients. An area under the
curve of the receiver operating characteristic (AUC of ROC) of 75-80 has been determined
compared to conventional coronary angiography using quantitative coronary angiography
(CCA-QCA). This indicates that the CADscore could potentially be used to diagnose CAD as a
supplement or risk stratification prior to CCTA.
We aim to evaluate the CADscore in a large clinical trial including 2000 patients that by
clinical indication undergo cCTA. After cCTA approximately 20 % (400 patients) will need
evaluation by CCA with FFR. CADscore results will be compared to CCTA and CCA-QCA.
Secondary, the CADscore will be compared to the results of CCA-FFR and perfusion scans,
Cardiac-MRI and SPECT.
Substudies
1. Perfusion scans
CCTA demonstrates good diagnostic performance for detection and exclusion of anatomic
coronary artery stenosis, but several studies have previously shown that CCTA has a low
positive predictive value for identification of hemodynamically significant CAD. This
emphasizes the need for additional tests to evaluate the severity (or exclusion) of
hemodynamically significant CAD. Measurement of FFR during CCA represents the "gold
standard" for assessment of the hemodynamic significance of coronary artery stenosis.
The disadvantage of CCA with FFR is that it is an invasive procedure.
After cCTA approximately 20 % (400 patients) will need further testing and that group
of patients will be randomized to either Cardiac MRI or SPECT followed by CCA with FFR.
The substudy aims to evaluate the diagnostic accuracy of perfusion imaging (Cardiac MRI
and SPECT) compared with CCA with FFR.
2. Virtual FFR
The accuracy and precision of virtual-FFR compared with conventional FFR will be determined.
Virtual FFR is computed from the coronary angiogram using computational fluid dynamics.
Subjects with diameter stenosis in the range of 30 to 90% by visual estimate in one or more
vessel segments with reference diameter ≥2.0 mm will be included in the analysis. FFR is the
reference standard to determine the presence or absence of hemodynamically significant
obstruction with a cut-off value of 0.80. Computation of vFFR with and without hyperaemia
will be compared.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |